Recently, more studies have focused on the combined efficacy of ER, PR, and Her-2 receptors since the 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to BC classification for therapeutic purposes based on the recognition of intrinsic biological subtypes[55]. This evidence concerns the gene ESR1 and breast cancer.